Mysore
Mysore
Mysore, Karnataka, India23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 3 | 2026-10-06 | NCT07861100 | |
| A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | MASH With Fibrosis; NASH With Fibrosis | Recruiting | Phase 3 | 2026-10-06 | NCT06215716 | |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT04906395 | |
| A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India | Female Urogenital Diseases and Pregnancy Complications, Hemorrhage, Obstetric Labor Complications, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postpartum Hemorrhage, Urogenital Diseases, Uterine Hemorrhage, pregnancy disorder, puerperal disorder | Recruiting | Phase 4 | 2026-09-25 | NCT07157423 | |
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis | acute pyelonephritis | Not yet recruiting | Phase 2 | 2026-09-24 | NCT07840105 | |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-09-21 | NCT06528314 | |
| Yoga Based Cardiac Rehabilitation in Heart Failure Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-09-14 | NCT07817589 | |
| HPTC Versus AFSM in Diabetic Foot Ulcers | Diabetes Complications, Diabetic Foot, Foot Ulcer, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, skin disorder, vascular disorder | Recruiting | Not applicable | 2026-09-10 | NCT07781917 | |
| A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Recruiting | Phase 2 | 2026-09-09 | NCT07431177 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Enrolling by invitation | Phase 3 | 2026-09-01 | NCT05645536 | |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | cardiovascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT05669755 | |
| Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-25 | NCT07669467 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic inducible urticaria, chronic urticaria, cold urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05976243 | |
| Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-08-19 | NCT06042478 | |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05869903 | |
| Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome | Body Weight, Dyslipidemias, Inflammation, Insulin Resistance, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, glucose metabolism disease, hyperinsulinism, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Recruiting | Not applicable | 2026-07-14 | NCT07703371 | |
| Development of Anti-Diabetic Nutraceuticals From Legume Seed Coats | Hyperglycemia, Postprandial, Insulin Resistance, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, metabolic syndrome X, type 2 diabetes mellitus | Enrolling by invitation | Not applicable | 2026-07-07 | NCT07688694 | |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-25 | NCT07669454 | |
| A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal disorder, gastric neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, stomach disorder, urinary system disorder | Recruiting | Phase 1 | 2026-04-17 | NCT05865002 | |
| ICU-related Out of Pocket Expenses (ICOPE) | Cost of ICU; Out of Pocket Expenses | Recruiting | Not stated | 2026-02-27 | NCT07439692 | |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2025-12-02 | NCT05620407 |